Unknown PHASE3 INTERVENTIONAL 2-arm NCT02232490

Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L (Hepko-V5)

Phase III Randomized, Placebo-controlled Clinical Trial of Hepcortespenlisimut-L (Hepko-V5) Versus Placebo in Patients With Advanced Hepatocellular Carcinoma (HCC)

Sponsor: Immunitor LLC

Conditions HCC Hepatocellular Carcinoma Liver Cancer

Interventions Placebo hepcortespenlisimut-L

Updated 9 times since 2017 Last updated: Feb 25, 2019 Started: Jan 31, 2015 Primary completion: Nov 30, 2019 Completion: Dec 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on HCC and Hepatocellular Carcinoma, this trial is ongoing. The trial is conducted by Immunitor LLC and has accumulated 9 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE3
Mar 2019 — Jan 2021 [monthly]

Recruiting PHASE3

▶ Show 4 earlier versions

Sep 2018 — Mar 2019 [monthly]

Recruiting PHASE3
Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE3
Apr 2017 — Jun 2018 [monthly]

Recruiting PHASE3
Jan 2017 — Apr 2017 [monthly]

Recruiting PHASE3

First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Immunitor LLC

Data source: Immunitor LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ulaanbaatar, Mongolia